STOCK TITAN

AnaptysBio, Inc. - ANAB STOCK NEWS

Welcome to our dedicated page for AnaptysBio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on AnaptysBio stock.

AnaptysBio, Inc. (Nasdaq: ANAB) is a clinical-stage biotechnology company dedicated to developing innovative immunology therapeutics to address unmet medical needs. Founded in 2005, AnaptysBio leverages its proprietary SHM-XEL platform to generate high-affinity therapeutic antibodies by harnessing the natural process of somatic hypermutation (SHM) under controlled conditions. The SHM-XEL platform mimics key features of the human immune system and overcomes the limitations of prior antibody technologies.

Headquartered in San Diego, AnaptysBio is focused on creating a robust pipeline of novel therapeutic antibody candidates targeting autoimmune, inflammatory, and oncology indications. The company boasts a portfolio that includes clinical-stage immune cell modulators such as rosnilimab (PD-1 agonist) and ANB032 (BTLA agonist), both in Phase 2 trials for rheumatoid arthritis (RA), ulcerative colitis (UC), and atopic dermatitis (AD).

AnaptysBio has shown significant progress in its clinical programs. Notably, the company reported positive top-line results from its global Phase 3 GEMINI-1 and GEMINI-2 trials evaluating imsidolimab (IL-36R mAb) for generalized pustular psoriasis (GPP). The results demonstrated rapid clearance of GPP symptoms with a single intravenous dose followed by effective maintenance with monthly subcutaneous doses.

Financially, AnaptysBio is on solid ground, reiterating a cash runway through year-end 2026 with expected year-end 2023 cash and investments of $400 to $410 million. The company's strategic collaborations, including its partnership with GSK for Jemperli (dostarlimab-gxly), provide additional financial support and validation of their therapeutic candidates' commercial potential.

Recently, AnaptysBio announced an exclusive license agreement with Centessa Pharmaceuticals for a BDCA2 modulator portfolio, including ANB101, further expanding its pipeline. The company plans to submit investigational new drug (IND) applications for ANB033 (anti-CD122 antagonist) and ANB101 in 2024.

With a commitment to patient-centric innovation and a strategic approach to partnerships and financial management, AnaptysBio continues to advance its mission of delivering transformative therapies to improve patients' lives globally.

Rhea-AI Summary

AnaptysBio, Inc. (Nasdaq: ANAB) reported financial results for Q1 2024, highlighting progress in Phase 2 trials for ANB032 and rosnilimab, with top-line data expected late 2024 and mid 2025, respectively. IND submissions for ANB033 and ANB101 planned for 2024. Positive Phase 3 trial results for imsidolimab. $50 million revenue from royalty monetization. Cash, cash equivalents, and investments at $370.1 million as of March 31, 2024, with a cash runway through 2026. Collaboration revenue increased to $7.2 million. Research and development expenses up, net loss of $43.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.75%
Tags
-
Rhea-AI Summary

AnaptysBio, Inc. announces positive top-line results from GEMINI-1 and GEMINI-2 Phase 3 trials for imsidolimab in treating generalized pustular psoriasis (GPP). Patients showed significant improvements in skin clearance with minimal flares. The company plans to out-license imsidolimab in 2024 after demonstrating favorable safety and tolerability profiles.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.75%
Tags
-
Rhea-AI Summary

AnaptysBio, a biotech company, is set to receive $50 million upfront cash payment from Sagard Healthcare as part of an amended agreement. The agreement involves additional royalties for Anaptys Jemperli, with Sagard potentially paying either $600 million by March 31, 2031, or $675 million thereafter. The funds will be used for the development of immune cell modulators in autoimmune and inflammatory diseases, strengthening Anaptys' balance sheet and supporting clinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.75%
Tags
none
Rhea-AI Summary
Actym Therapeutics, a company focusing on a new drug modality for treating solid tumors, appoints Thomas Smart as the Chief Executive Officer. With 25 years of experience in the biopharmaceutical industry, Mr. Smart brings expertise in corporate development, strategic planning, and R&D translation. His appointment comes as Actym gears up for the clinical evaluation of its lead candidate, ACTM-838, showcasing a novel approach through the STACT platform at upcoming conferences. Smart's leadership aims to drive corporate growth, expand the pipeline, and maximize the therapeutic potential of ACTM-838.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
management
-
Rhea-AI Summary
AnaptysBio, Inc. reports operating results for Q4 and year-end 2023, with cash and investments of $417 million and plans for ongoing clinical trials and new IND filings. The company aims to bring transformational medicines for autoimmune and inflammatory diseases, with top-line data expected for various trials by 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
-
Rhea-AI Summary
AnaptysBio, Inc. (ANAB) announces participation in investor conference and medical meeting to present preclinical data on ANB032 for atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
Rhea-AI Summary
AnaptysBio, Inc. (ANAB) announces the participation of its CEO, Daniel Faga, in Guggenheim’s 6th Annual Biotechnology Conference. The event will feature a fireside chat and a live webcast, providing investors with an opportunity to engage with the company's leadership and gain insights into its innovative immunology therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
-
Rhea-AI Summary
AnaptysBio, Inc. (ANAB) licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio from Centessa Pharmaceuticals (CNTA). Anaptys anticipates filing an IND application for the lead asset ANB101 in H2 2024. The company reiterates year-end 2023 cash and investments of $400 to $410 million and cash runway through year-end 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Summary
AnaptysBio, Inc. (ANAB) Named BioSpace 2024 Best Place to Work for Second Consecutive Year
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
none
Rhea-AI Summary
AnaptysBio, Inc. has initiated a global Phase 2b trial for rheumatoid arthritis (RA) treatment with rosnilimab. They are also starting a Phase 2 trial for ulcerative colitis (UC) treatment with rosnilimab. The company announced positive Phase 3 trial results for imsidolimab in generalized pustular psoriasis (GPP). They expect to have a cash runway through year-end 2026 and anticipate having $400 to $410 million in cash and investments by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.21%
Tags

FAQ

What does AnaptysBio specialize in?

AnaptysBio specializes in developing therapeutic antibodies for autoimmune, inflammatory, and oncology diseases using its proprietary SHM-XEL platform.

What are the key clinical programs of AnaptysBio?

AnaptysBio's key clinical programs include immune cell modulators like rosnilimab (PD-1 agonist) and ANB032 (BTLA agonist), both in Phase 2 trials for rheumatoid arthritis, ulcerative colitis, and atopic dermatitis.

What recent achievements has AnaptysBio reported?

AnaptysBio recently reported positive top-line results from its Phase 3 GEMINI-1 and GEMINI-2 trials evaluating imsidolimab for generalized pustular psoriasis, demonstrating effective treatment and maintenance.

What are AnaptysBio's financial highlights?

AnaptysBio reiterates a cash runway through year-end 2026, with expected year-end 2023 cash and investments of $400 to $410 million, supported by strategic collaborations and licensing agreements.

What is the SHM-XEL platform?

The SHM-XEL platform is AnaptysBio's proprietary technology that replicates the human immune system's antibody maturation process to generate high-affinity therapeutic antibodies.

Who are AnaptysBio's strategic partners?

AnaptysBio's strategic partners include GSK, with whom they collaborate on the development and commercialization of Jemperli (dostarlimab-gxly) and other therapeutic antibodies.

What is the focus of AnaptysBio's preclinical immune cell modulator portfolio?

AnaptysBio's preclinical immune cell modulator portfolio focuses on advancing candidates like ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) for autoimmune and inflammatory diseases.

How does AnaptysBio's SHM-XEL platform benefit their antibody development?

The SHM-XEL platform allows AnaptysBio to generate high-affinity, fully human therapeutic antibodies with optimal properties such as high affinity, function, cross-reactivity, and manufacturability.

What are the recent licensing agreements by AnaptysBio?

AnaptysBio recently entered an exclusive license agreement with Centessa Pharmaceuticals for a BDCA2 modulator portfolio, including the lead asset ANB101.

What are AnaptysBio's plans for 2024?

In 2024, AnaptysBio plans to move ANB033 and ANB101 into clinical development with IND submissions, and continue advancing its clinical trials for rosnilimab and ANB032.

AnaptysBio, Inc.

Nasdaq:ANAB

ANAB Rankings

ANAB Stock Data

920.64M
27.32M
1.93%
111.48%
16.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO